Pirfenidone (Standard)

Pirfenidone (Standard) is the analytical standard of Pirfenidone. This product is intended for research and analytical applications. Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].

Product Specifications

CAS Number

[53179-13-8]

Product Name Alternative

AMR69 (Standard)

UNSPSC

12352005

Hazard Statement

H302

Target

CCR; Reference Standards; TGF-beta/Smad

Type

Reference Standards

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Others; Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/pirfenidone-standard.html

Purity

99.97

Smiles

O=C1C=CC(C)=CN1C2=CC=CC=C2

Molecular Formula

C12H11NO

Molecular Weight

185.22

Precautions

H302

References & Citations

[1]Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354 (2) :542-7.|[2]Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446 (1-3) :177-85.|[3]Yang Y, et al. Inhibition of Pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transitionof human lens epithelial cells line SRA01/04. PLoS One. 2013;8 (2) :e56837.|[4]Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16.|[5]Brooks D, et al. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018 May 4;9 (34) :23462-23481.